CINECA IRIS Institutional Research Information System

GATTO, Mariele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.932
NA - Nord America 1.628
SA - Sud America 642
EU - Europa 564
AF - Africa 48
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.819
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.600
SG - Singapore 1.267
CN - Cina 717
BR - Brasile 535
KR - Corea 393
IT - Italia 301
VN - Vietnam 201
IN - India 156
DE - Germania 52
GB - Regno Unito 44
JP - Giappone 43
AR - Argentina 42
FI - Finlandia 34
HK - Hong Kong 31
ID - Indonesia 31
EC - Ecuador 28
RU - Federazione Russa 25
NL - Olanda 22
BD - Bangladesh 18
AT - Austria 17
ES - Italia 14
IE - Irlanda 14
IQ - Iraq 14
CO - Colombia 12
FR - Francia 11
MX - Messico 11
PY - Paraguay 10
ZA - Sudafrica 9
MA - Marocco 8
UZ - Uzbekistan 8
CA - Canada 6
CI - Costa d'Avorio 6
NP - Nepal 6
PK - Pakistan 5
PL - Polonia 5
SA - Arabia Saudita 5
TR - Turchia 5
UA - Ucraina 5
AE - Emirati Arabi Uniti 4
DZ - Algeria 4
EE - Estonia 4
GR - Grecia 4
JO - Giordania 4
KE - Kenya 4
TW - Taiwan 4
AU - Australia 3
CL - Cile 3
CR - Costa Rica 3
EG - Egitto 3
IR - Iran 3
LV - Lettonia 3
PE - Perù 3
TN - Tunisia 3
UY - Uruguay 3
VE - Venezuela 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
JM - Giamaica 2
KW - Kuwait 2
LT - Lituania 2
PA - Panama 2
SE - Svezia 2
SN - Senegal 2
TG - Togo 2
TH - Thailandia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BH - Bahrain 1
CU - Cuba 1
GA - Gabon 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LY - Libia 1
MK - Macedonia 1
MU - Mauritius 1
MY - Malesia 1
NG - Nigeria 1
PH - Filippine 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
YT - Mayotte 1
Totale 5.819
Salva come PNG Salva come JPEG
Città #
Santa Clara 871
Singapore 699
Hefei 402
Seoul 389
Bengaluru 136
Turin 123
Columbus 120
Beijing 114
Ho Chi Minh City 96
Buffalo 57
Los Angeles 50
Dallas 42
São Paulo 41
Redondo Beach 40
Tokyo 32
Hanoi 30
Hong Kong 27
Ashburn 25
Rio de Janeiro 22
Milan 20
New York 20
Curitiba 17
Helsinki 16
Lappeenranta 15
Brasília 14
Dublin 14
Belo Horizonte 13
Falkenstein 13
Nuremberg 13
Haiphong 12
Chicago 11
Jakarta 11
Vienna 10
Biên Hòa 9
Quito 9
Torino 9
Frankfurt am Main 8
Guayaquil 8
Heidelberg 8
Tashkent 8
London 7
Rome 7
San Diego 7
Santo André 7
Abidjan 6
Amsterdam 6
Betim 6
Brooklyn 6
Medellín 6
Padova 6
Salvador 6
Uberlândia 6
West Jordan 6
Baghdad 5
Boardman 5
Bologna 5
Buenos Aires 5
Manaus 5
Mexico City 5
Moscow 5
Noale 5
Shenzhen 5
The Dalles 5
Warsaw 5
Wuhan 5
Assago 4
Bắc Giang 4
Conegliano 4
Contagem 4
Düsseldorf 4
Elk Grove Village 4
Fulham 4
Goiânia 4
Gravesend 4
Grugliasco 4
Guarulhos 4
Hangzhou 4
Jeddah 4
Kathmandu 4
Manchester 4
Nairobi 4
Santa Maria 4
Silver Spring 4
Treviso 4
Verona 4
Al Ain City 3
Asunción 3
Bogotá 3
Brescia 3
Cabo Frio 3
Cabo de Santo Agostinho 3
Campinas 3
Capannori 3
Ciudad del Este 3
Da Nang 3
Delhi 3
Farnborough 3
Ha Long 3
Holzkirchen 3
Houston 3
Totale 3.841
Salva come PNG Salva come JPEG
Nome #
Early disease and Low baseline damage as predictors of response to Belimumab in patients with systemic lupus erythematosus in a real-life setting 148
Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry 117
Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis 93
B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools 78
O25 Lupus podocytopathy: a rare form of lupus nephritis – an Italian retrospective multicenter study 71
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease 66
CHARACTERIZATION OF EXTRACELLULAR VESICLES SURFACE LYMPHOCYTES MARKERS AND MICRORNA CARGO IN PATIENTS AFFECTED WITH IDIOPATHIC INFLAMMATORY MYOPATHIES 65
Remission in systemic lupus erythematosus: Testing different definitions in a large multicentre cohort 65
B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab 65
MicroRNAs in idiopathic inflammatory myopathies: state-of-the-art and future perspectives 61
Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis 60
CCL18 as a Biomarker of Interstitial Lung Disease (ILD) and Progressive Fibrosing ILD in Patients with Idiopathic Inflammatory Myopathies 58
Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease 57
Assessment of disease activity and damage in SLE: Are we there yet? 57
CLINICAL FEATURES AND RENAL PROGNOSIS IN LUPUS NEPHRITIS PATIENTS UNDERGOING A REPEATED BIOPSY: RESULTS OF 103 RE-BIOPSIES IN 438 PATIENTS 56
SERPINB3 Delays Glomerulonephritis and Attenuates the Lupus-Like Disease in Lupus Murine Models by Inducing a More Tolerogenic Immune Phenotype 56
Autophagy in human health and disease 55
Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up 55
Anti-MDA5 dermatomyositis: an update from bench to bedside 55
Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review 54
Size-Exclusion Chromatography Combined with Ultrafiltration Efficiently Isolates Extracellular Vesicles from Human Blood Samples in Health and Disease 53
Advances in the Diagnosis and Classification of Systemic Lupus Erythematosus 53
Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention 53
Success and failure of biological treatment in systemic lupus erythematosus: A critical analysis 53
Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus 52
O43 Three years is the minimal effective duration of sustained clinical remission associated with reduced risk of impaired kidney function and of damage accrual in lupus nephritis 52
Autoantibody testing in patients with myositis: clinical accuracy of a multi parametric line immunoassay 51
ISEV2022 Abstract Book 51
New therapeutic strategies in systemic lupus erythematosus management 51
Effectiveness and safety of low dose Rituximab as remission-maintenance treatment for patients with refractory idiopathic inflammatory myopathies: results of a retrospective study from a monocentric cohort 51
IMMUNOSUPPRESSANT WITHDRAWAL AFTER REMISSION ACHIEVEMENT IN LUPUS NEPHRITIS: EFFECT ON FLARE OCCURRENCE 50
Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis 50
Belimumab: a step forward in the treatment of systemic lupus erythematosus 50
Characterization of Serum Cytokine Profiles of Patients with Active Lupus Nephritis 50
CHANGES IN CIRCULATING B CELL LEVELS AND IMMUNOPHENOTYPE ARE ASSOCIATED WITH DEVELOPMENT OF ARTHRITIS FOLLOWING TREATMENT WITH CHECKPOINT INHIBITORS 50
Circulating extracellular vesicles and small non-coding RNAs cargo in idiopathic inflammatory myopathies reveal differences across myositis subsets 49
AB0558 ANIFROLUMAB IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS: A REAL-LIFE, MULTICENTER STUDY 49
The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients 48
Modern Management of Pregnancy in Systemic Lupus Erythematosus: From Prenatal Counseling to Postpartum Support 48
Retention Rate of Ixekizumab in Psoriatic Arthritis: A Real-World Study 48
Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab 47
The Retention Rate and Safety of JAK Inhibitors in Rheumatoid Arthritis: Real Word Data from a Monocentric Cohort 47
Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint-Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor-Induced Inflammatory Arthritis 47
Preclinical and early systemic lupus erythematosus 47
O11 Unsupervised machine-learning identifies distinct clusters based on B cell phenotyping and autoantibody profiles in patients with systemic lupus erythematosus 47
17-β-estradiol affects BLyS serum levels and the nephritogenic autoantibody network accelerating glomerulonephritis in NZB/WF1 mice 46
Effectiveness, Tolerability, and Safety of Belimumab in Patients with Refractory SLE: a Review of Observational Clinical-Practice-Based Studies 46
Transcriptional network profile on synovial fluid T cells in psoriatic arthritis 46
Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate 46
Should ACR/EULAR criteria be revised changing the RF and ACPA scores? 46
Anifrolumab In Refractory Systemic Lupus Erythematosus: A Real-Life, Multicenter Study 46
Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: Data from a large multicentric cohort 45
Early and Late Response and Glucocorticoid-Sparing Effect of Belimumab in Patients with Systemic Lupus Erythematosus with Joint and Skin Manifestations: Results from the Belimumab in Real Life Setting Study-Joint and Skin (BeRLiSS-JS) 45
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 45
Serpins, Immunity and Autoimmunity: Old Molecules, New Functions 44
In-/off-label use of biologic therapy in systemic lupus erythematosus 44
When to use belimumab in SLE 44
Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus 44
Evaluation of extracellular vesicles as potential myositis biomarkers 44
POS1515 PREVALENCE AND CLINICAL FEATURES OF LATE AND VERY LATE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS 44
Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus 44
Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission 43
Diagnostic and prognostic role of renal histopathology in rheumatic diseases 43
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management 43
Recent findings in idiopathic inflammatory myopathies with potential diagnostic and therapeutic implications 42
Physician’s global assessment is often useful in SLE, but not always: the case of clinical remission 42
Cardiovascular risk factors, burden of disease and preventive strategies in patients with systemic lupus erythematosus: A literature review 42
Predictors of maternal and fetal complications in SLE patients: a prospective study 42
Monoclonal antibodies targeting interleukins for systemic lupus erythematosus: updates in early clinical drug development 42
P79 Clinical features and prevalence of late and very late onset systemic lupus erythematosus 42
Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis 42
The role of musculoskeletal ultrasound in difficult-to-treat RA: Insights from a systematic literature review 41
Evaluation of extracellular vesicles as potential biomarkers of myositis 41
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort 41
Nonimmune mechanisms in idiopathic inflammatory myopathies 41
PTX3, Anti-PTX3, and Anti-C1q Autoantibodies in Lupus Glomerulonephritis 41
Role of galectin-3 in autoimmune and non-autoimmune nephropathies 41
Thoracic Involvement in Systemic Autoimmune Rheumatic Diseases: Pathogenesis and Management 41
Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study 40
Current clinical and therapeutic approach to tumour-like mass lesions in granulomatosis with polyangiitis 39
POS1510 IDENTIFICATION OF THE MINIMAL REQUIRED DURATION OF RENAL-EXTRARENAL REMISSION ASSOCIATED WITH REDUCED RISK OF CHRONIC KIDNEY DISEASE AND OF DAMAGE ACCRUAL IN LUPUS NEPHRITIS 39
Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis 39
Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: findings from a multicentre study on 122 cases 39
Clinical presentation, outcomes and risk of relapses of lupus podocytopathy in a multicentre Italian cohort 39
SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients 38
Emerging and critical issues in the pathogenesis of lupus 38
Immunization with Pentraxin3 prevents transition from subclinical to clinical lupus nephritis in lupus-prone mice: insights from renal ultrastructural findings.   38
Serpins as players in autoimmune diseases 38
Retention rate and predictors of discontinuation for secukinumab treatment: real-life data in a cohort of patients with spondyloarthritis 38
Defining the targets in SLE management: insights and unmet gaps 38
The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study 38
Lymphocyte immunophenotyping in inflammatory myositis: a review 38
Detection of Myositis Autoantibodies by Multi-Analytic Immunoassays in a Large Multicenter Cohort of Patients with Definite Idiopathic Inflammatory Myopathies 38
New onset sarcoidosis following biologic treatment in patients with seronegative inflammatory arthritis: A case series and systematic literature review 37
Maternal outcome in pregnant women with lupus nephritis. A prospective multicenter study 36
Is per-protocol kidney biopsy required in lupus nephritis? 36
Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus 35
Controversies in Rheumatology and Autoimmunity: Approaching the truth by the discussion 35
Overlap connective tissue disease syndromes 35
What are the topics you care about making trials in lupus more effective? Results of an Open Space meeting of international lupus experts 33
Totale 4.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.155
article - articoli 0
book - libri 0
conference - conferenze 2.269
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.424
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202112 0 0 0 0 1 2 4 1 0 3 0 1
2021/20229 0 0 3 0 0 0 1 0 2 0 0 3
2022/20236 1 0 0 0 0 2 1 0 0 2 0 0
2023/2024371 1 1 0 62 16 18 5 58 14 38 47 111
2024/20252.780 18 216 48 257 771 258 55 60 154 144 222 577
2025/20262.742 363 782 384 1.076 137 0 0 0 0 0 0 0
Totale 5.980